NCT02923401 is a NA clinical trial of Exercise in Disorders of Breast, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT02923401?

NCT02923401 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02923401?

Interventions in NCT02923401: Exercise, Questionnaires, Motivational Session, Phone Call, Printed Materials.

What condition does NCT02923401 study?

NCT02923401 studies Disorders of Breast.

Is NCT02923401 still recruiting?

NCT02923401 is currently completed. Last updated 28 February 2022.

Last reviewed 2022-02-28 · How we verify

NCT02923401

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer

Completed NA Last updated 28 February 2022

What this trial tests

NA trial testing Exercise in Disorders of Breast in 39 participants. Completed in 5 January 2022.

Timeline

30 September 2016

Primary endpoint
5 January 2022

5 January 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	39
Start date	30 September 2016
Primary completion	5 January 2022
Estimated completion	5 January 2022
Sites	1 location across United States

Drugs / interventions tested

Exercise
Questionnaires
Motivational Session
Phone Call
Printed Materials

Conditions studied

Disorders of Breast — all drugs for Disorders of Breast →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 55, female only, with Disorders of Breast. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this research study is to learn if there is a level of exercise training that is more effective in lowering biomarker levels that are linked to breast cancer risk. Biomarkers are found in the blood/tissue and may be related to your reaction to exercise. This is an investigational study. Up to 72 participants will be enrolled in this study. All will take part at MD Anderson.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Physical Activity as an Imperative Support in Breast Cancer Management.
Ortega MA, Fraile-Martínez O, García-Montero C, Pekarek L, et al · · 2020 · cited 34× · PMID 33379177 · DOI 10.3390/cancers13010055
The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.
Coletta AM, Agha NH, Baker FL, Niemiro GM, et al · · 2021 · cited 33× · PMID 33555464 · DOI 10.1007/s10549-021-06111-z
High-Intensity Interval Training Is Feasible in Women at High Risk for Breast Cancer.
Coletta AM, Brewster AM, Chen M, Li Y, et al · · 2019 · cited 10× · PMID 31269007 · DOI 10.1249/mss.0000000000002048
Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategies.
Li F, Gao C, Huang Y, Qiao Y, et al · · 2025 · cited 8× · PMID 40303301 · DOI 10.7150/ijbs.108803

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07589725 — Mulligan Mobilization in Lateral Elbow Tendinopathy · NA · not yet recruiting
NCT07524400 — Effects of Physical Exercise Combined With Transcranial Direct Current Stimulation in Parkinson's Disease · NA · recruiting
NCT06627569 — Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans · NA · not yet recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02923401 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 28 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02923401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing